

AstraZeneca, BMS gets FDA nod for diabetes drug

09 January 2014 | Regulatory | By BioSpectrum Bureau



Singapore: AstraZeneca and Bristol-Myers Squibb have received U.S. Food and Drug Administration (FDA) approval for diabetes drug Farxiga (dapagliflozin).

AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control.